Anagliptin

• CAT Number: I004746
• CAS Number: 739366-20-2
• Molecular Formula: C19H25N7O2
• Molecular Weight: 383.45
• Purity: ≥95%
• Target: Dipeptidyl Peptidase
• Solubility: DMSO: ≥ 36 mg/mL
• Storage: Store at -20°C
• IC50: 3.8 nM
• IUPAC Name: N-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
• InChI: InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1
• InChIKey: LDXYBEHACFJIEL-HNNXBMFYSA-N
• SMILES: O=C(C1=CN2C(N=C1)=CC(C)=N2)NCC(C)(NCC(N3[C@H](C#N)CCC3)=O)C

Anagliptin（Cat No.:I004746）is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes. By inhibiting DPP-4, an enzyme that breaks down incretin hormones such as GLP-1, anagliptin increases the levels of these hormones, which in turn enhances insulin secretion and reduces glucagon release in response to meals. This helps lower blood glucose levels. Anagliptin is typically prescribed as an adjunct to diet and exercise, either alone or in combination with other antidiabetic agents. It is generally well tolerated, with mild side effects such as gastrointestinal discomfort.